Tirzepatide, a novel agent approved by the Food and Drug Administration for the treatment of obesity and type 2 diabetes, is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.